These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27498128)

  • 1. IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.
    Lakhanpal R; Sestak I; Shadbolt B; Bennett GM; Brown M; Phillips T; Zhang Y; Bullman A; Rezo A
    Breast; 2016 Oct; 29():147-52. PubMed ID: 27498128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
    Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
    Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
    Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
    J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
    Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
    J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
    J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer.
    Park CC; Rembert J; Chew K; Moore D; Kerlikowske K
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):75-9. PubMed ID: 18692323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
    Selz J; Stevens D; Jouanneau L; Labib A; Le Scodan R
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1123-32. PubMed ID: 22572073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
    Albert JM; Gonzalez-Angulo AM; Guray M; Sahin A; Strom EA; Tereffe W; Woodward WA; Tucker SL; Hunt KK; Hortobagyi GN; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1296-302. PubMed ID: 20472353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
    Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locoregional recurrence in patients with HER2 positive breast cancer.
    Brollo J; Kneubil MC; Botteri E; Rotmensz N; Duso BA; Fumagalli L; Locatelli MA; Criscitiello C; Lohsiriwat V; Goldhirsch A; Leonardi MC; Orecchia R; Curigliano G
    Breast; 2013 Oct; 22(5):856-62. PubMed ID: 23642529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
    van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
    Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
    Barton S; Zabaglo L; A'Hern R; Turner N; Ferguson T; O'Neill S; Hills M; Smith I; Dowsett M
    Br J Cancer; 2012 May; 106(11):1760-5. PubMed ID: 22531639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
    Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.